Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

404 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Melanoma Adjuvant Treatment: Current Insight and Clinical Features.
D'Aniello C, Perri F, Scarpati GDV, Pepa CD, Pisconti S, Montesarchio V, Wernert N, Zarone MR, Caraglia M, Facchini G, Berretta M, Cavaliere C. D'Aniello C, et al. Among authors: berretta m. Curr Cancer Drug Targets. 2018;18(5):442-456. doi: 10.2174/1568009617666170208163714. Curr Cancer Drug Targets. 2018. PMID: 28183255 Review.
Optimal Management of Prostate Cancer Based on its Natural Clinical History.
Facchini G, Perri F, Misso G, D'Aniello C, Scarpati GDV, Rossetti S, Pepa CD, Pisconti S, Unteregger G, Cossu A, Caraglia M, Berretta M, Cavaliere C. Facchini G, et al. Among authors: berretta m. Curr Cancer Drug Targets. 2018;18(5):457-467. doi: 10.2174/1568009617666170209093101. Curr Cancer Drug Targets. 2018. PMID: 28183253 Review.
Current and Emerging Treatments for Metastatic Renal Cell Carcinoma.
Cavaliere C, D'Aniello C, Pepa CD, Pisconti S, Berretta M, Facchini G. Cavaliere C, et al. Among authors: berretta m. Curr Cancer Drug Targets. 2018;18(5):468-479. doi: 10.2174/1568009617666170209094030. Curr Cancer Drug Targets. 2018. PMID: 28183256 Review.
Predictive Comprehensive Geriatric Assessment in elderly prostate cancer patients: the prospective observational scoop trial results.
Della Pepa C, Cavaliere C, Rossetti S, Di Napoli M, Cecere SC, Crispo A, De Sangro C, Rossi E, Turitto D, Germano D, Iovane G, Berretta M, D'Aniello C, Pisconti S, Maiorino L, Daniele B, Gridelli C, Pignata S, Facchini G. Della Pepa C, et al. Among authors: berretta m. Anticancer Drugs. 2017 Jan;28(1):104-109. doi: 10.1097/CAD.0000000000000428. Anticancer Drugs. 2017. PMID: 27579728
Biomarkers of Prognosis and Efficacy of Anti-angiogenic Therapy in Metastatic Clear Cell Renal Cancer.
D'Aniello C, Berretta M, Cavaliere C, Rossetti S, Facchini BA, Iovane G, Mollo G, Capasso M, Pepa CD, Pesce L, D'Errico D, Buonerba C, Di Lorenzo G, Pisconti S, De Vita F, Facchini G. D'Aniello C, et al. Among authors: berretta m. Front Oncol. 2019 Dec 11;9:1400. doi: 10.3389/fonc.2019.01400. eCollection 2019. Front Oncol. 2019. PMID: 31921657 Free PMC article. Review.
From Clinical Trials to the Front Line: Vinflunine for Treatment of Urothelial Cell Carcinoma at the National Cancer Institute of Naples.
Facchini G, Della Pepa C, Cavaliere C, Cecere SC, Di Napoli M, D'Aniello C, Crispo A, Iovane G, Maiolino P, Tramontano T, Piscitelli R, Pisconti S, Montella M, Berretta M, Sorrentino D, Perdonà S, Pignata S. Facchini G, et al. Among authors: berretta m. Front Pharmacol. 2016 May 3;7:110. doi: 10.3389/fphar.2016.00110. eCollection 2016. Front Pharmacol. 2016. PMID: 27199753 Free PMC article.
Very Early PSA Response to Abiraterone in mCRPC Patients: A Novel Prognostic Factor Predicting Overall Survival.
Facchini G, Caffo O, Ortega C, D'Aniello C, Di Napoli M, Cecere SC, Della Pepa C, Crispo A, Maines F, Ruatta F, Iovane G, Pisconti S, Montella M, Berretta M, Pignata S, Cavaliere C. Facchini G, et al. Among authors: berretta m. Front Pharmacol. 2016 May 18;7:123. doi: 10.3389/fphar.2016.00123. eCollection 2016. Front Pharmacol. 2016. PMID: 27242530 Free PMC article.
404 results